TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Price Performance

TXMD opened at $1.67 on Friday. The stock’s 50-day moving average price is $1.75 and its 200 day moving average price is $1.93. TherapeuticsMD has a 12-month low of $1.43 and a 12-month high of $3.15.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter. The company had revenue of $0.23 million during the quarter.

Institutional Investors Weigh In On TherapeuticsMD

Hedge funds have recently bought and sold shares of the stock. Prosperity Consulting Group LLC acquired a new stake in TherapeuticsMD in the 1st quarter valued at about $56,000. ADAR1 Capital Management LLC purchased a new position in shares of TherapeuticsMD in the 4th quarter valued at about $612,000. Finally, Clearline Capital LP increased its holdings in shares of TherapeuticsMD by 18.9% in the 2nd quarter. Clearline Capital LP now owns 636,622 shares of the company’s stock valued at $1,025,000 after acquiring an additional 101,282 shares during the last quarter. Institutional investors and hedge funds own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.